Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2016. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely discloses the acquisition of shares by a PDMR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction under the GSK ShareReward Plan.
Important Facts for Investors
- Transaction Date: Shares were acquired on March 9, 2016.
- Share Price: 1404.27 pence per Ordinary Share.
- Participant: Mr. S A Hussain (PDMR).
- Acquisition Details: 8 shares acquired via the personal contribution element and 8 shares via the matching element (GSK contribution) of the ShareReward Plan.
- Signatory: Victoria Whyte, Company Secretary, signed the report on March 11, 2016.